Medical Consortium for Screening Upper Gastrointestinal Cancers With Magnetically Controlled Capsule Gastroscopy
NCT ID: NCT04032353
Last Updated: 2019-07-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
10000 participants
INTERVENTIONAL
2018-12-31
2020-03-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Cohort Study of Mobile Capsule Gastroscopy for Gastric Pathologies Screening
NCT07032961
Magnetically Controlled Capsule Endoscopy in Visualization of the UGI and Small Intestine
NCT05069233
Associations Among Serum and Gastric Juice Bile Acid Profile, Bile Acid-microbiota Cross-talk in Stomach and the Development of Gastric Cancer
NCT04660058
The Second-Generation MCCG for Upper Gastrointestinal Tract.
NCT03977935
Correlation of Endoscopic Findings and Symptoms in Patients Undergoing the First Upper Gastrointestinal Endoscopy
NCT03736824
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
SCREENING
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Medical Consortium
subjects involved in medical consortium for screening upper gastrointestinal canccers(MCSC)
Medical Consortium
subjects received intensive follow-up by coordinators according to the predifined protocol of MCSC
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Medical Consortium
subjects received intensive follow-up by coordinators according to the predifined protocol of MCSC
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* subjects able to give informed consent
Exclusion Criteria
* inoperability of refusal to accept any abdominal surgery;
* dysphagia or gastric paralysis;
* previous history of gastrointestinal disease;
* with pacemaker, implanted-cardiac defibrillator or other implanted electromedical devices;
* need for standard magnetic resonance imaging examination within seven days after swallowing the MCCG, unless the capsule is confirmed to have been excreted;
* other factors that are not suitable for inclusion evaluated by medical stuff
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Yanqing Li
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Yanqing Li
vice president of Qilu Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Gastroenterology, Qilu Hospital, Shandong University
Jinan, Shandong, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2019SDU-QILU-150
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.